David Bresticker, MD
Family Medicine · Williamsport, PANPI 1376582841
Payments from drug & device makers
Across 222 payments — averaging $13.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$493
- AbbVie$435
- Pfizer$246
- Lilly USA, LLC$234
- Amgen$218
- Astellas Pharma US Inc$213
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,00097%
- Education$873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 34 | $493 |
| AbbVie(2 entities) | 23 | $435 |
| Pfizer | 28 | $246 |
| Lilly USA, LLC | 19 | $234 |
| Amgen | 16 | $218 |
| Astellas Pharma US Inc | 13 | $213 |
| Boehringer Ingelheim | 17 | $191 |
| AstraZeneca | 10 | $189 |
| Novo Nordisk | 10 | $150 |
| Johnson & Johnson | 16 | $148 |
| E.r. Squibb & Sons, L.L.C. | 4 | $90 |
| Novartis | 6 | $86 |
| Genentech USA, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 3 | $34 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Grifols USA, LLC | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Biogen | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Medtronic | 1 | $14 |
| Braeburn Inc. | 1 | $14 |
How this compares
$3,087 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 226 | $172,810 |
| JardianceEmpagliflozin | 164 | $141,207 |
| OzempicSemaglutide | 104 | $110,511 |
| TrulicityDulaglutide | 53 | $52,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $47,245 |
| TradjentaLinagliptin | 42 | $37,259 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 78 | $34,188 |
| FarxigaDapagliflozin Propanediol | 31 | $32,498 |
| XareltoRivaroxaban | 34 | $30,026 |
| MyrbetriqMirabegron | 54 | $29,999 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $21,379 |
| ProliaDenosumab | 12 | $20,620 |
| JanuviaSitagliptin Phosphate | 22 | $19,317 |
| MounjaroTirzepatide | 17 | $17,071 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 44 | $15,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $191 | $199,846244 claims |
| PfizerEliquis, Premarin, Paxlovid | $246 | $184,113267 claims |
| Novo NordiskOzempic | $150 | $110,511104 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $493 | $88,050151 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $234 | $69,31270 claims |
| AstraZenecaFarxiga | $189 | $32,49831 claims |
| Johnson & JohnsonXarelto | $148 | $30,02634 claims |
| Astellas Pharma US IncMyrbetriq | $213 | $29,99954 claims |
| AmgenProlia | $218 | $20,62012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Williamsport
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.